Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
1.500
-0.010 (-0.66%)
Sep 23, 2026, 9:54 AM EDT - Market open
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
8.42M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 500.00K | - | - |
| Dec 31, 2021 | 500.00K | - | - |
| Dec 31, 2020 | 500.00K | - | - |
| Dec 31, 2019 | 500.00K | - | - |
| Dec 31, 2018 | 500.00K | - | - |
| Dec 31, 2017 | 500.00K | - | - |
| Dec 31, 2016 | 500.00K | - | - |
| Dec 31, 2015 | 500.00K | - | - |
| Dec 31, 2014 | 500.00K | - | - |
| Dec 31, 2013 | 500.00K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 2.00M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 2.50M | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Traws Pharma | 2.73M |
| Evogene | 1.66M |
| Longeveron | 1.19M |
| Exicure | 500.00K |
| CollPlant Biotechnologies | 389.00K |
| Soligenix | 2.34K |
IMNN News
- 1 day ago - Imunon announces IDMC recommends continued Phase 2 development of IMNN-001 - TheFly
- 1 day ago - IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review - GlobeNewsWire
- 13 days ago - Imunon enters CRADA with National Cancer Institute for IMNN-001 development - TheFly
- 13 days ago - IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 - GlobeNewsWire
- 14 days ago - IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress - GlobeNewsWire
- 4 weeks ago - IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 - GlobeNewsWire
- 6 weeks ago - Imunon Earnings Call Transcript: Q2 2026 - Transcripts
- 6 weeks ago - Imunon Earnings release: Q2 2026 - Filings